SOURCE: BJPsych Open. 6(6) (no pagination), 2020. Article Number: e131.
Read MoreWelcome to TMS Solutions' resource portal, Solute, where you will find the latest informative articles about mental health, neuromodulation techniques, and TMS.
Relevant Posts
Sep 25, 2022 6:16:00 PM
Baseline Predictors of Cognitive Change in the Treatment of Major Depressive Episode: Systematic Review
Sep 8, 2022 11:26:00 AM
Bilateral Repetitive Transcranial Magnetic Stimulation Ameliorated Sleep Disorder and Hypothalamic-Pituitary-Adrenal Axis Dysfunction in Subjects With Major Depression
Sep 5, 2022 12:24:00 PM
A Polygenic-Informed Approach to a Predictive EEG Signature Empowers Antidepressant Treatment Prediction: A Proof-of-Concept Study
SOURCE: European Neuropsychopharmacology. 62:49-60, 2022 Sep.
AUTHORS: Meijs H; Prentice A; Lin BD; De Wilde B; Van Hecke J; Niemegeers P; van Eijk K; Luykx JJ; Arns M
ABSTRACT: The treatment of major depressive disorder (MDD) is hampered by low chances of treatment response in each treatment step, which is partly due to a lack of firmly established outcome-predictive biomarkers. Here, we hypothesize that polygenic-informed EEG signatures may help predict antidepressant treatment response. Using a polygenic-informed electroencephalography (EEG) data-driven, data-reduction approach, we identify a brain network in a large cohort (N=1,123), and discover it is sex-specifically (male patients, N=617) associated with polygenic risk score (PRS) of antidepressant response. Subsequently, we demonstrate in three independent datasets the utility of the network in predicting response to antidepressant medication (male, N=232) as well as repetitive transcranial magnetic stimulation (rTMS) and concurrent psychotherapy (male, N=95). This network significantly improves a treatment response prediction model with age and baseline severity data (area under the curve, AUC=0.623 for medicaton; AUC=0.719 for rTMS). A predictive model for MDD patients, aimed at increasing the likelihood of being a responder to antidepressants or rTMS and concurrent psychotherapy based on only this
network, yields a positive predictive value (PPV) of 69% for medication and 77% for rTMS. Finally, blinded out-of-sample validation of the network as predictor for psychotherapy response in another independent dataset (male, N=50) results in a within-subsample response rate of 50% (improvement of 56%). Overall, the findings provide a first proof-of-concept of a combined genetic and neurophysiological approach in the search for clinically-relevant biomarkers in psychiatric disorders, and should encourage researchers to incorporate genetic information, such as PRS, in their search for clinically relevant neuroimaging biomarkers.
Sep 3, 2022 6:01:00 PM
